Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE) (ARCHIVE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04641013 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 23, 2020
Last Update Posted : November 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| HIV Infections Aging |
| Study Type : | Observational [Patient Registry] |
| Actual Enrollment : | 446 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Target Follow-Up Duration: | 10 Years |
| Official Title: | Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE): a follow-on Study of the Australian Positive & Peers Longevity Evaluation Study |
| Actual Study Start Date : | December 5, 2017 |
| Actual Primary Completion Date : | April 17, 2019 |
| Estimated Study Completion Date : | December 4, 2027 |
| Group/Cohort |
|---|
| People with HIV over the age of 55 years |
| People without HIV over the age of 55 years |
- Proportion of participants with at least one somatic mutation associated with clonal haematopoiesis [ Time Frame: 2017-2019 ]Detection of mutations associated with clonal haematopoiesis
- Median and natural log-transformed Interleukin-6 [ Time Frame: 2017-2019 ]Interleukin-6 level
- Median (IQR) and natural log-transformed C-reactive protein and Cystatin C; D-dimer >0.27 [ Time Frame: 2017-2019 ]C-reactive protein, Cystatin C, D-dimer
- Median (IQR) and natural log-transformed Haemoglobin [ Time Frame: 2017-2019 ]Haemoglobin
- Median (IQR) and natural log-transformed White blood cell count, Median (IQR) and natural log-transformed Neutrophil count, natural log-transformed Lymphocyte count, natural log-transformed platelet count [ Time Frame: 2017-2019 ]White blood cell count, Neutrophil count, Lymphocyte count, platelet count
- natural log-transformed Mean corpuscular volume [ Time Frame: 2017-2019 ]mean corpuscular volume
- natural log transformed Red Cell distribution width [ Time Frame: 2017-2019 ]red cell distribution width
- Proportion of participants with diagnosed cardiovascular conditions, any malignancy, haematologic malignancies [ Time Frame: 2017-2019 ]Comorbid conditions
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Men and women aged >55
- For participants without HIV: an HIV negative test within 12 months prior to enrolment. If no HIV-negative test result is available within 12 months prior to enrolment, then participants will be tested for HIV as part of standard of care, if indicated by the guidelines for HIV testing published by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine14. This study will not conduct HIV testing; therefore, any participants without HIV being considered for participation in the study will need to have had a standard of care HIV negative test within the past 12 months. Some subjects at on-going risk for HIV are recommended to have periodic HIV testing and may be due for such testing as part of standard of care, at the time of enrolment into the study.
- Willing and able to provide written informed consent and willingness to participate in and comply with a longitudinal cohort study including 1) consent to providing blood samples for full blood count, inflammatory marker testing and genomics analysis 2) consent to linking their data to national and state-wide data registries (including consent to providing personally identifying information); and 3) consent to participate in future follow-up studies
Exclusion Criteria:
- Unwilling or unable to provide consent to participate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04641013
| Australia, New South Wales | |
| St Vincent's Hospital HIV, Immunology and Infectious Disease Unit | |
| Darlinghurst, New South Wales, Australia, 2010 | |
| Albion Street Centre | |
| Sydney, New South Wales, Australia, 2010 | |
| East Sydney Doctors | |
| Sydney, New South Wales, Australia, 2010 | |
| Holdsworth House Medical Practice | |
| Sydney, New South Wales, Australia, 2010 | |
| Kirby Institute | |
| Sydney, New South Wales, Australia, 2010 | |
| Taylor Square Private Clinic | |
| Sydney, New South Wales, Australia, 2010 | |
| RPA Sexual Health, Royal Prince Alfred Hospital, Camperdown | |
| Sydney, New South Wales, Australia, 2050 | |
| Australia, Victoria | |
| Alfred Hospital | |
| Melbourne, Victoria, Australia, 3004 | |
| Prahran Market Clinic | |
| Melbourne, Victoria, Australia, 3141 | |
| Monash Medical Centre | |
| Melbourne, Victoria, Australia, 3168 | |
| Peter MacCallum Cancer Centre | |
| Melbourne, Victoria, Australia | |
| Principal Investigator: | Mark Polizzotto, MBBS, PhD | Kirby Institute, UNSW Sydney | |
| Principal Investigator: | Nila Dharan, MD | Kirby Institute, UNSW Sydney | |
| Principal Investigator: | Kathy Petoumenos, PhD | Kirby Institute, UNSW Sydney |
| Responsible Party: | Kirby Institute |
| ClinicalTrials.gov Identifier: | NCT04641013 |
| Other Study ID Numbers: |
2020-11-ARCHIVE |
| First Posted: | November 23, 2020 Key Record Dates |
| Last Update Posted: | November 23, 2020 |
| Last Verified: | November 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |

